Bos AB - Search Results

1

High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.

Ohri R, Bhakta S, Fourie-O'Donohue A, Dela Cruz-Chuh J, Tsai SP, Cook R, Wei B, Ng C, Wong AW, Bos AB, Farahi F, Bhakta J, Pillow TH, Raab H, Vandlen R, Polakis P, Liu Y, Erickson H, Junutula JR, Kozak KR. Ohri R, et al. Among authors: bos ab. Bioconjug Chem. 2018 Feb 21;29(2):473-485. doi: 10.1021/acs.bioconjchem.7b00791. Epub 2018 Feb 9. Bioconjug Chem. 2018. PMID: 29425028

2

Development of a semi-automated high throughput transient transfection system.

Bos AB, Duque JN, Bhakta S, Farahi F, Chirdon LA, Junutula JR, Harms PD, Wong AW. Bos AB, et al. J Biotechnol. 2014 Jun 20;180:10-6. doi: 10.1016/j.jbiotec.2014.03.027. Epub 2014 Apr 1. J Biotechnol. 2014. PMID: 24704608

3

Optimization and automation of an end-to-end high throughput microscale transient protein production process.

Bos AB, Luan P, Duque JN, Reilly D, Harms PD, Wong AW. Bos AB, et al. Biotechnol Bioeng. 2015 Sep;112(9):1832-42. doi: 10.1002/bit.25601. Epub 2015 Jul 7. Biotechnol Bioeng. 2015. PMID: 25851051

4

Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands.

Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Bos AB, et al. Int J Cancer. 2006 Nov 15;119(10):2372-5. doi: 10.1002/ijc.22114. Int J Cancer. 2006. PMID: 16858676 Free article.

5

[Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996].

Bos AB, van Ballegooijen M, van den Akker-van Marle ME, Habbema JD. Bos AB, et al. Ned Tijdschr Geneeskd. 2002 Aug 24;146(34):1586-90. Ned Tijdschr Geneeskd. 2002. PMID: 12224483 Dutch.

6

Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening.

Bos AB, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Bos AB, et al. Eur J Cancer. 2002 Apr;38(6):827-31. doi: 10.1016/s0959-8049(02)00026-6. Eur J Cancer. 2002. PMID: 11937318

7

Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears.

Bos AB, van Ballegooijen M, van den Akker-van Marle ME, Hanselaar AG, van Oortmarssen GJ, Habbema JD. Bos AB, et al. Am J Clin Pathol. 2001 Jun;115(6):851-5. doi: 10.1309/RP84-MD34-8MFN-39UR. Am J Clin Pathol. 2001. PMID: 11392881

8

The diagnostic value of computer-assisted primary cervical smear screening: a longitudinal cohort study.

Doornewaard H, van der Schouw YT, van der Graaf Y, Bos AB, Habbema JD, van den Tweel JG. Doornewaard H, et al. Among authors: bos ab. Mod Pathol. 1999 Nov;12(11):995-1000. Mod Pathol. 1999. PMID: 10574595 Clinical Trial.

9

Observer variation in cytologic grading for cervical dysplasia of Papanicolaou smears with the PAPNET testing system.

Doornewaard H, van der Schouw YT, van der Graaf Y, Bos AB, van den Tweel JG. Doornewaard H, et al. Among authors: bos ab. Cancer. 1999 Aug 25;87(4):178-83. doi: 10.1002/(sici)1097-0142(19990825)87:4<178::aid-cncr3>3.0.co;2-1. Cancer. 1999. PMID: 10455204

10

Organised cervical cancer screening still leads to higher coverage than spontaneous screening in The Netherlands.

Bos AB, van Ballegooijen M, van Gessel-Dabekaussen AA, Habbema JD. Bos AB, et al. Eur J Cancer. 1998 Sep;34(10):1598-601. doi: 10.1016/s0959-8049(98)00249-4. Eur J Cancer. 1998. PMID: 9893635

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page